EYPT EyePoint Pharmaceuticals
- 8.690
- -0.320-3.55%
EyePoint Pharmaceuticals News
Mizuho Securities Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $30
Mizuho Securities analyst Graig Suvannavejh maintains $EyePoint Pharmaceuticals(EYPT.US)$ with a buy rating, and maintains the target price at $30.According to TipRanks data, the analyst has a success
Capital One Financial Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35
Capital One Financial analyst Tim Chiang maintains $EyePoint Pharmaceuticals(EYPT.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success ra
EyePoint Pharmaceuticals(EYPT.US) Director Sells US$119.7K in Common Stock
$EyePoint Pharmaceuticals(EYPT.US)$ Director GUYER DAVID R sold 11,625 shares of common stock on Jun 3, 2024 at an average price of $10.2972 for a total value of $119.7K.Source: Announcement What is s
EyePoint Pharmaceuticals Is Maintained at Overweight by JP Morgan
EyePoint Pharmaceuticals Is Maintained at Overweight by JP Morgan
JPMorgan Adjusts EyePoint Pharmaceuticals Price Target to $32 From $35, Maintains Overweight Rating
EyePoint Pharmaceuticals (EYPT) has an average rating of Buy and price targets ranging from $28 to $68, according to analysts polled by Capital IQ.
Express News | EyePoint Pharmaceuticals Inc : JP Morgan Cuts Target Price to $32 From $35
Buy Rating Affirmed for EyePoint Pharmaceuticals Amidst Promising Phase 3 Trials and FDA Alignment
Investing in EyePoint Pharmaceuticals (NASDAQ:EYPT) a Year Ago Would Have Delivered You a 91% Gain
Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)
EyePoint Pharmaceuticals(EYPT.US) Director Sells US$147.04K in Common Stock
$EyePoint Pharmaceuticals(EYPT.US)$ Director GUYER DAVID R sold 11,625 shares of common stock on May 14, 2024 at an average price of $12.649 for a total value of $147.04K.Source: Announcement What is
Crocs To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Jefferies c
EyePoint Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
EyePoint Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
EyePoint Pharmaceuticals: Maintaining Buy Rating Amidst Progress and Trials
Express News | EyePoint Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $30 From $33
EyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite Challenges
EyePoint Pharmaceuticals | 10-Q: Quarterly report
Buy Rating Affirmed for EyePoint Pharmaceuticals Amidst Positive Duravyu Trial Insights and Future Prospects
EyePoint Pharmaceuticals(EYPT.US) 10% Shareholder Buys US$10.08 Million in Common Stock
$EyePoint Pharmaceuticals(EYPT.US)$ 10% Shareholder Cormorant Asset Management, LP purchased 850K shares of common stock on May 6, 2024 at an average price of $11.86 for a total value of $10.08 millio
Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating
EyePoint Pharmaceuticals (EYPT) has an average rating of buy and price targets ranging from $28 to $68, according to analysts polled by Capital IQ. Price: 11.68, Change: -0.19, Percent Change: -1.60
Express News | EyePoint Pharmaceuticals' Q1 Cash And Investments On March 31, 2024 Of $299M Is Expected To Provide Cash Runway Into 2026
Analysis
Price Target
No Data
